Metabolomics and Lipidomics Profiling Reveals Hypocholesterolemic and Hypolipidemic Effects of Arabinoxylan on Type 2 Diabetic Rats.

Abstract

Type 2 diabetes (T2D) is a pandemic disease chiefly characterized by hyperglycemia. In this study, the combination of serum lipidomic and metabolomic approach was employed to investigate the effect of arabinoxylan on type 2 diabetic rats and identify the critical biomarkers of T2D. Metabolomics analysis revealed that branched-chain amino acids, 12α-hydroxylated bile acids, ketone bodies, and several short- and long-chain acylcarnitines were significantly increased in T2D, whereas lysophosphatidylcholines (LPCs) were significantly decreased. Lipidomics analysis indicated T2D-related dyslipidemia was mainly associated with the increased levels of acetylcarnitine, free fatty acids (FFA), diacylglycerols, triacylglycerols, and cholesteryl esters and the decreased levels of some unsaturated phosphatidylcholines (less than 22 carbons). These variations indicated the disturbed amino acid and lipid metabolism in T2D, and the accumulation of incompletely oxidized lipid species might eventually contribute to impaired insulin action and glucose homeostasis. Arabinoxylan treatment decreased the concentrations of 12α-hydroxylated bile acids, carnitines, and FFAs and increased the levels of LPCs. The improved bile acid and lipid metabolism by arabinoxylan might be involved in the alleviation of hypercholesterolemia and hyperlipidemia in T2D.

• Authors: Qixing Nie, Mengmeng Xing, Haihong Chen, Jielun Hu, Shaoping Nie
• Journal: Journal of agricultural and food chemistry (J Agric Food Chem) Vol. 67 Issue 38 Pg. 10614-10623 (Sep 25 2019) ISSN: 1520-5118 [Electronic] United States
• PMID: 31483658 (Publication Type: Journal Article)

Chemical References

• Amino Acids, Branched-Chain
• Anticholesteremic Agents
• Bile Acids and Salts
• Fatty Acids, Nonesterified
• Hypoglycemic Agents
• Hypolipidemic Agents
• Lipids
• Xylans
• arabinoxylan
• Glucose
• Carnitine

Topics

• Amino Acids, Branched-Chain (metabolism)
• Animals
• Anticholesteremic Agents (administration & dosage)
• Bile Acids and Salts (metabolism)
• Carnitine (metabolism)
• Diabetes Mellitus, Type 2 (complications, drug therapy, metabolism)
• Fatty Acids, Nonesterified (metabolism)
• Glucose (metabolism)
• Humans
• Hypercholesterolemia (drug therapy, etiology, metabolism)
• Hyperlipidemias (drug therapy, etiology, metabolism)
• Hypoglycemic Agents (administration & dosage)
• Hypolipidemic Agents (administration & dosage)
• Lipid Metabolism
• Lipids (chemistry)
• Metabolomics
• Rats
• Xylans (administration & dosage)